Healthcare Wrap: Debt Deals, FDA Wins and Revenue Growth Drive Week 28 Movers

Argent BioPharma (ASX:RGT) led the week with a 100.00% jump after licensing CannEpil globally to Splash Beverage Group. Investors cared because the deal did two simple things at once. It removed US$5.5 million of secured debt through debt forgiveness, and it kept a 15% royalty on future sales. That improved the balance sheet and left Argent holding its intellectual property and manufacturing rights. Imugene (ASX:IMU) was the sharpest faller at 22.22%. The company raised $11.12 million to push azer-cel forward after early data showed complete responses in two patients in a small combination group. Even so, the stock gave back ground after re-opening, which suggests early gains evaporated as traders locked in profits. Island Pharmaceuticals (ASX:ILA) rose 20.00% after government approvals in Uganda supported compassionate use of Galidesivir during an Ebola outbreak. That news matters because it moves the drug closer to real-world human data. Yet the share price slipped well below its re-open level later in the week, so buying did not hold.

Sales growth stood out

Mesoblast (ASX:MSB) added 8.74% after Ryoncil posted US$36 million in fourth-quarter revenue and US$115 million for the year. Investors responded to hard sales numbers, not just trial news. Ryoncil is already approved by the US Food and Drug Administration, which means doctors can prescribe it, and uptake across US paediatric centres looks strong. Compumedics (ASX:CMP) slipped 4.17% despite record FY26 revenue of $60.3 million. The result itself was solid, with recurring software revenue up 70%, but the stock still fell, which can happen when investors had already expected a strong report. Cogstate (ASX:CGS) moved the other way, climbing 5.84% after booking a record $89 million in FY26 sales contracts and lifting its FY27 backlog to $118.5 million. A backlog is work already signed but not yet fully counted as revenue, so it gives investors more visibility on future income.

Approvals opened doors

Optiscan Imaging (ASX:OIL) gained 14.81% after launching InSpecta in the US veterinary market. This was its first FDA-cleared clinical device sale, which matters because clearance is a key gate before commercial selling in the US. The product lets vets view tissue at the cellular level in real time, or while the animal is being treated, and the company is now entering a market worth nearly US$16 billion. Proteomics International (ASX:PIQ) rose 2.50% after winning a US patent for PromarkerEndo, its blood test for endometriosis. Investors liked the protection through 2041 because patents can help a company license or sell a product without immediate copycat competition. Botanix Pharmaceuticals (ASX:BOT) climbed 14.29% after the European Patent Office signalled it intended to grant a patent covering the Sofdra applicator. Unlike some gap moves that fade, sustained buying followed the re-open, which suggests investors kept backing the news through the week.

Cash still matters in biotech

Several smaller healthcare names reminded investors that trial progress often depends on having enough money to keep going. Imugene now has new cash to support clinical work, manufacturing and regulatory steps. In plain terms, that helps pay for patient studies, drug supply and the paperwork needed before wider approval. ReNerve (ASX:RNV) was flat at 0.00% for the week but stayed busy on two fronts. It won approval to market its NervAlign Nerve Cuff in Indonesia and also secured a A$5 million convertible note facility to help fund US expansion. The first item opens a new market. The second brings cash, but investors will also watch future share dilution, which means more shares may be issued later. Noxopharm (ASX:NOX) fell 1.09% after requesting a pre-IND meeting with the FDA for SOF-SKN. That meeting is an early discussion with the regulator before a human trial application. It is useful, but it does not guarantee approval or a fast trial start.

Clinical progress was mixed

Alterity Therapeutics (ASX:ATH) dropped 5.22% even after the FDA confirmed that one pivotal Phase 3 trial could support approval for ATH434 in multiple system atrophy. A pivotal trial is the large final study usually needed before a drug can be approved. The update was positive, but investors may be waiting for the actual trial launch later in 2026 rather than buying on process news alone. Dimerix (ASX:DXB) was flat at 0.00% after opening post-trial access to DMX-200 for eligible kidney disease patients. That step helps patients stay on treatment after the main study ends, but it does not provide fresh efficacy data. Nexalis Therapeutics (ASX:NX1) also finished flat at 0.00%, though the story behind that number was less calm. The company ended funding talks with Point8 Capital, cancelled a funding facility and suspended trials pending new money, even as its Phase 1 study for IRX-616a reported no serious adverse events. In simple terms, the early safety result was good, but cash uncertainty is now the bigger issue.

Healthcare services and aged care stayed steady

Promisia Healthcare (ASX:PHL) reported record occupancy of 96% in June and kept its FY27 underlying earnings target of NZD8 million. Occupancy matters in aged care because full beds usually mean stronger revenue. Aldwins House improved from 89% to 98%, which shows the turnaround is happening site by site. PainChek (ASX:PCK) rose 15.00% after chief executive Philip Daffas stepped down and chief operating officer Andy Hoggan took over on an interim basis. Leadership changes can worry investors, but this move was tied to a push into the US after FDA clearance, and the stock held above its re-open level. Zoono Group (ASX:ZNO) edged up 1.85% after quarterly cash receipts rose 94% and the business turned cash-flow positive. That result matters because it shows customer orders are turning into cash rather than just trial activity or early talks.